Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Maximum budget of $275,000 over a maximum of two years.
To promote preclinical and patient-based studies examining the mechanisms through which incretin mimetics impact cancer risk.
Researchers in cancer biology, healthcare professionals, and patients affected by obesity-related cancers.
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, small businesses, local, state, and federal governments, and foreign organizations.
Specific qualifications include having a 501(c)(3) status for some nonprofits, and compliance with NIH registration requirements.
Open to U.S. and non-domestic entities, including foreign organizations.
Focus on mechanisms of incretin mimetics and their impact on cancer risk.
Studies must evaluate mechanisms influenced by incretin mimetics in animal models or human studies.
Direct costs limited to $275,000 over two years, with no more than $200,000 in any single year.
Application due date is January 7, 2027.
Earliest submission date is January 16, 2025.
No restrictions on prior grant funding mentioned.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
Applications will be evaluated based on significance, innovation, approach, and investigator expertise.
Applications undergo peer review and are assessed for scientific and technical merit.
Priority given to innovative research addressing significant gaps in knowledge.
Only applications that do not propose clinical trials are accepted.
Applicants must justify the choice of incretin mimetics other than GLP-1 RAs.
Encouragement for applicants to contact NCI staff early in the application development process.
Research must focus on mechanisms rather than epidemiological endpoints.
Strong justification for the proposed research and adherence to application guidelines.
Submitting applications that do not comply with the specified instructions.
Engage with NIH staff early to clarify any uncertainties regarding the application.
Highlight innovative aspects of the research and its potential impact on cancer risk understanding.